Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Aerovance is a Berkeley, Calif.-based company that is focused on the development and commercialization of biologics for respiratory and inflammatory diseases. The company’s lead products are AerovantÔ, an IL4/13 receptor antagonist for severe asthma and eczema that is currently in Phase 2 clinical studies, and AerolyticÔ, a recombinant protein for the treatment of cystic fibrosis and chronic obstructive pulmonary disease that is currently in Phase 2 clinical studies. In addition to these investigational products, Aerovance has several preclinical programs in respiratory disease. ( www.aerovance.com )
Aerovance , Inc.
2929 Seventh Street Suite 130
Berkeley, California 94710
USA
Tel: (510) 549-5500
Fax: (510) 549-5501